BioScrip (BIOS) Upgraded to Buy by BidaskClub
BioScrip (NASDAQ:BIOS) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Saturday.
BIOS has been the subject of several other reports. ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. BioScrip presently has an average rating of “Buy” and an average price target of $3.63.
BioScrip (NASDAQ BIOS) traded up $0.02 during mid-day trading on Friday, hitting $3.15. 1,002,322 shares of the stock traded hands, compared to its average volume of 729,064. BioScrip has a 1 year low of $1.35 and a 1 year high of $3.39. The stock has a market capitalization of $399.12, a price-to-earnings ratio of -4.63 and a beta of 0.04. The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.